SEC Form 4	
------------	--

 $\square$ 

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OWR APPRC	VAL
OMB Number:	3235-0287
Estimated average burd	en
hours per response:	0.5

1 I Nume and Address of Reporting Leson			2. Issuer Name <b>and</b> Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]		tionship of Reporting Pers all applicable) Director	10% Owner
(Last) 14 CAMBRIDG	(Last) (First) (Middle) 14 CAMBRIDGE CENTER		3. Date of Earliest Transaction (Month/Day/Year) 11/01/2009	X	Officer (give title below) SVP, Chief Account	Other (specify below) ng Officer
(Street) CAMBRIDGE	МА	02142	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing Form filed by One Repo Form filed by More thar	orting Person
(City)	(State)	(Zip)			Person	

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Disposed Of 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount (A) or (D) Price		Transaction(s) (Instr. 3 and 4)		(11150. 4)	
Common Stock	11/01/2009		М		1,000	Α	\$ <mark>0</mark>	25,067.9467	D	
Common Stock	11/01/2009		F		418	D	\$42.13	24,649.9467 <sup>(2)</sup>	D	

 
 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date	3A. Deemed Execution Date,	4. Transa		of	of Expiration Date A			7. Title an Amount o	f	8. Price of Derivative	9. Number of derivative	10. Ownership	11. Nature of Indirect
Security (Instr. 3)	or Exercise Price of Derivative Security	(Month/Day/Year)	if any (Month/Day/Year)	Code ( 8)	linstr.	Sec Acq (A) Disp of (I (Ins	Derivative (Month/Day/Year) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Unit	\$0	11/01/2009		М			1,000	(1)	10/31/2016	Common Stock	1,000	\$0	0	D	

Explanation of Responses:

1. The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 11/01/2006.

2. Includes 421.3008 shares acquired under the Biogen Idec Inc. employee stock purchase plan on 3/31/2009.

<u>Aras Lapinskas, Attorney in</u> Fact for Michael F. MacLean

11/03/2009

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.